US10816469B2 - Kit for quantitatively determining substance to be measured in biological sample and method for quantitatively determining substance to be measured in biological sample - Google Patents
Kit for quantitatively determining substance to be measured in biological sample and method for quantitatively determining substance to be measured in biological sample Download PDFInfo
- Publication number
- US10816469B2 US10816469B2 US16/115,593 US201816115593A US10816469B2 US 10816469 B2 US10816469 B2 US 10816469B2 US 201816115593 A US201816115593 A US 201816115593A US 10816469 B2 US10816469 B2 US 10816469B2
- Authority
- US
- United States
- Prior art keywords
- measured
- substance
- antibody
- binding
- blocking agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 239000000126 substance Substances 0.000 title claims abstract description 240
- 238000000034 method Methods 0.000 title claims abstract description 114
- 239000012472 biological sample Substances 0.000 title claims abstract description 57
- 239000002245 particle Substances 0.000 claims abstract description 157
- 238000009739 binding Methods 0.000 claims abstract description 118
- 239000002981 blocking agent Substances 0.000 claims abstract description 95
- 239000000758 substrate Substances 0.000 claims abstract description 91
- 238000001514 detection method Methods 0.000 claims abstract description 43
- 102000009027 Albumins Human genes 0.000 claims abstract description 26
- 108010088751 Albumins Proteins 0.000 claims abstract description 26
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 102
- 229940098773 bovine serum albumin Drugs 0.000 claims description 82
- 239000004816 latex Substances 0.000 claims description 45
- 229920000126 latex Polymers 0.000 claims description 45
- 238000006243 chemical reaction Methods 0.000 claims description 30
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 24
- 229910052737 gold Inorganic materials 0.000 claims description 24
- 239000010931 gold Substances 0.000 claims description 24
- 108060003951 Immunoglobulin Proteins 0.000 claims description 18
- 102000018358 immunoglobulin Human genes 0.000 claims description 18
- 230000005284 excitation Effects 0.000 claims description 15
- 239000007795 chemical reaction product Substances 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 abstract description 11
- 239000008280 blood Substances 0.000 abstract description 11
- 239000003613 bile acid Substances 0.000 description 77
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 74
- 238000005259 measurement Methods 0.000 description 68
- 239000000243 solution Substances 0.000 description 46
- 230000003053 immunization Effects 0.000 description 38
- 229960000890 hydrocortisone Drugs 0.000 description 37
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 36
- 238000002649 immunization Methods 0.000 description 35
- 241000699666 Mus <mouse, genus> Species 0.000 description 33
- 239000000427 antigen Substances 0.000 description 32
- 102000036639 antigens Human genes 0.000 description 32
- 108091007433 antigens Proteins 0.000 description 32
- 229910052751 metal Inorganic materials 0.000 description 27
- 239000002184 metal Substances 0.000 description 27
- 238000002965 ELISA Methods 0.000 description 24
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 23
- 239000004380 Cholic acid Substances 0.000 description 20
- 239000002671 adjuvant Substances 0.000 description 20
- 229960002471 cholic acid Drugs 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 20
- 210000000941 bile Anatomy 0.000 description 19
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 18
- 229960003964 deoxycholic acid Drugs 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 239000000523 sample Substances 0.000 description 17
- 102000006395 Globulins Human genes 0.000 description 16
- 108010044091 Globulins Proteins 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 239000007864 aqueous solution Substances 0.000 description 15
- 238000005119 centrifugation Methods 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 13
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 12
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 12
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 12
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 12
- 235000019416 cholic acid Nutrition 0.000 description 12
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 12
- 239000000839 emulsion Substances 0.000 description 12
- 238000001917 fluorescence detection Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 230000008859 change Effects 0.000 description 11
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 10
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- 230000002860 competitive effect Effects 0.000 description 10
- 210000004408 hybridoma Anatomy 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 210000004989 spleen cell Anatomy 0.000 description 9
- 239000007987 MES buffer Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 239000012228 culture supernatant Substances 0.000 description 8
- 238000010494 dissociation reaction Methods 0.000 description 8
- 230000005593 dissociations Effects 0.000 description 8
- 230000016784 immunoglobulin production Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 206010003445 Ascites Diseases 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical class CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 239000007853 buffer solution Substances 0.000 description 7
- 229920001577 copolymer Polymers 0.000 description 7
- 230000003100 immobilizing effect Effects 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 7
- 239000004926 polymethyl methacrylate Substances 0.000 description 7
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000004364 calculation method Methods 0.000 description 6
- 238000011088 calibration curve Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000011259 mixed solution Substances 0.000 description 6
- 201000000050 myeloid neoplasm Diseases 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- 241000282326 Felis catus Species 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 238000000691 measurement method Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 102100032752 C-reactive protein Human genes 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000004520 agglutination Effects 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000001837 anti-cortisol effect Effects 0.000 description 4
- 230000007910 cell fusion Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000002296 dynamic light scattering Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 4
- 150000002923 oximes Chemical class 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 3
- LLQHSBBZNDXTIV-UHFFFAOYSA-N 6-[5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC1CC(=NO1)C1=CC2=C(NC(O2)=O)C=C1 LLQHSBBZNDXTIV-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 239000006087 Silane Coupling Agent Substances 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 238000004040 coloring Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- 210000004754 hybrid cell Anatomy 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 239000013545 self-assembled monolayer Substances 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- -1 specifically Polymers 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 0 *B=S.*B=S.CC(=O)O.CC(=O)O.CC(=O)ON1C(=O)CCC1=O.CN.CNC(C)=O.[H][C@@]12C[C@H](O)CC[C@]1(C)[C@@]1([H])C[C@H](O)[C@]3(C)[C@@H]([C@H](C)CCC(=O)O)CC[C@@]3([H])[C@]1([H])[C@H](O)C2 Chemical compound *B=S.*B=S.CC(=O)O.CC(=O)O.CC(=O)ON1C(=O)CCC1=O.CN.CNC(C)=O.[H][C@@]12C[C@H](O)CC[C@]1(C)[C@@]1([H])C[C@H](O)[C@]3(C)[C@@H]([C@H](C)CCC(=O)O)CC[C@@]3([H])[C@]1([H])[C@H](O)C2 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920000297 Rayon Polymers 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 238000007720 emulsion polymerization reaction Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 150000002443 hydroxylamines Chemical class 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000001755 magnetron sputter deposition Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000005304 optical glass Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002094 self assembled monolayer Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 2
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000004544 sputter deposition Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- JQXYBDVZAUEPDL-UHFFFAOYSA-N 2-methylidene-5-phenylpent-4-enoic acid Chemical compound OC(=O)C(=C)CC=CC1=CC=CC=C1 JQXYBDVZAUEPDL-UHFFFAOYSA-N 0.000 description 1
- 229920005509 ACRYPET® VH Polymers 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920005497 Acrypet® Polymers 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- QHTKOVFCGXPNCI-YLLFPQNTSA-N CO.COCC(=O)O.C[C@]12C[C@H](O)C3C(CCC4=CC(=O)CC[C@@]43C)C1CC[C@]2(O)C(=O)CO.Cl.[H]C1=C2CCC3C4CC[C@](C)(C(=O)CO)[C@@]4(C)C[C@H](O)C3[C@@]2(C)CCC1=NOCOC=O Chemical compound CO.COCC(=O)O.C[C@]12C[C@H](O)C3C(CCC4=CC(=O)CC[C@@]43C)C1CC[C@]2(O)C(=O)CO.Cl.[H]C1=C2CCC3C4CC[C@](C)(C(=O)CO)[C@@]4(C)C[C@H](O)C3[C@@]2(C)CCC1=NOCOC=O QHTKOVFCGXPNCI-YLLFPQNTSA-N 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 description 1
- ILMSXHWECVBZNY-JFBVGOEOSA-N [H][C@@]12C[C@H](O)CC[C@]1(C)[C@@]1([H])CC[C@]3(C)[C@@H]([C@H](C)CCC(=O)O)CC[C@@]3([H])[C@]1([H])[C@H](O)C2.[H][C@@]12C[C@H](O)CC[C@]1(C)[C@@]1([H])C[C@H](O)[C@]3(C)[C@@H]([C@H](C)CCC(=O)O)CC[C@@]3([H])[C@]1([H])[C@H](O)C2.[H][C@]12C[C@H](O)[C@]3(C)[C@@H]([C@H](C)CCC(=O)O)CC[C@@]3([H])[C@]1([H])CC[C@]1([H])C[C@H](O)CC[C@]21C Chemical compound [H][C@@]12C[C@H](O)CC[C@]1(C)[C@@]1([H])CC[C@]3(C)[C@@H]([C@H](C)CCC(=O)O)CC[C@@]3([H])[C@]1([H])[C@H](O)C2.[H][C@@]12C[C@H](O)CC[C@]1(C)[C@@]1([H])C[C@H](O)[C@]3(C)[C@@H]([C@H](C)CCC(=O)O)CC[C@@]3([H])[C@]1([H])[C@H](O)C2.[H][C@]12C[C@H](O)[C@]3(C)[C@@H]([C@H](C)CCC(=O)O)CC[C@@]3([H])[C@]1([H])CC[C@]1([H])C[C@H](O)CC[C@]21C ILMSXHWECVBZNY-JFBVGOEOSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- WRVRNZNDLRUXSW-UHFFFAOYSA-N acetic acid;prop-2-enoic acid Chemical compound CC(O)=O.OC(=O)C=C WRVRNZNDLRUXSW-UHFFFAOYSA-N 0.000 description 1
- XECAHXYUAAWDEL-UHFFFAOYSA-N acrylonitrile butadiene styrene Chemical compound C=CC=C.C=CC#N.C=CC1=CC=CC=C1 XECAHXYUAAWDEL-UHFFFAOYSA-N 0.000 description 1
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 238000004630 atomic force microscopy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003858 bile acid conjugate Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- SQNNHEYXAJPPKH-UHFFFAOYSA-N chloroethene;prop-2-enoic acid Chemical compound ClC=C.OC(=O)C=C SQNNHEYXAJPPKH-UHFFFAOYSA-N 0.000 description 1
- RPKLZQLYODPWTM-KBMWBBLPSA-N cholanoic acid Chemical group C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)CC2 RPKLZQLYODPWTM-KBMWBBLPSA-N 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 208000015829 congenital portosystemic shunt Diseases 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 150000001886 cortisols Chemical class 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000007772 electroless plating Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000009713 electroplating Methods 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 230000010235 enterohepatic circulation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- CYKDLUMZOVATFT-UHFFFAOYSA-N ethenyl acetate;prop-2-enoic acid Chemical compound OC(=O)C=C.CC(=O)OC=C CYKDLUMZOVATFT-UHFFFAOYSA-N 0.000 description 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229920001109 fluorescent polymer Polymers 0.000 description 1
- 239000003574 free electron Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 238000009532 heart rate measurement Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000016178 immune complex formation Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007733 ion plating Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000007561 laser diffraction method Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- QIWKUEJZZCOPFV-UHFFFAOYSA-N phenyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OC1=CC=CC=C1 QIWKUEJZZCOPFV-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000004915 pus Anatomy 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000001370 static light scattering Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000007740 vapor deposition Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
- G01N33/553—Metal or metal coated
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
Definitions
- the present invention relates to a kit for quantitatively determining a substance to be measured in a biological sample and a method for quantitatively determining a substance to be measured in a biological sample.
- a fluorescence detection method has been in wide use as a highly sensitive and simple measurement method for quantitatively determining a substance to be measured such as proteins, enzymes, and inorganic compounds which are contained in a biological sample.
- the fluorescence detection method is a method in which fluorescence emitted in a case where a sample considered to include a substance to be measured which is excited by light of a specific wavelength so as to emit fluorescence, is irradiated with excitation light of the specific wavelength, is detected, and thus the presence of the substance to be measured is confirmed.
- the substance to be measured is not a fluorescent substance
- a substance that specifically binds to the substance to be measured is labeled with a fluorescent dye and brought into contact with a sample, and thereafter, in the same manner as above, fluorescence emitted in a case where the sample is irradiated with the excitation light is detected, and thus the presence of the substance to be measured can be confirmed.
- a method utilizing the effect of electric field enhancement by plasmon resonance has been known.
- a sensor chip including a metal film provided in a predetermined region on a transparent support is prepared.
- the excitation light is allowed to enter an interface between the support and the metal film from a side opposite to the metal film formation surface of the support at an angle equal to or greater than a total reflection angle.
- Surface plasmons are generated in the metal film by irradiation with the excitation light, fluorescence is enhanced by the electric field enhancement effect due to generation of the surface plasmons, and therefore a signal/noise ratio (S/N ratio) is improved.
- a signal enhancement of about 10 times as compared with a fluorescence detection method by epi-excitation (hereinafter, will be referred to as “epifluorescence method”) is obtained, and thus high sensitive measurement is possible.
- JP2014-235081A discloses an immunostaining method for detecting an antigen in a pathological tissue immobilized on a surface of a substrate glass treated with an amino group-containing silane coupling agent by immunostaining using fluorescent nanoparticles, the method including a step of adding a blocking agent to the pathological tissue immobilized on the surface of the substrate glass treated with the amino group-containing silane coupling agent; a step of adding an antibody reactive to an antigen to the pathological tissue; a step of adding a compound (1) having a functional group capable of reacting with an amino group in the amino group-containing silane coupling agent, and allowing the compound to be left alone at room temperature for a predetermined time; and a step of adding fluorescent nanoparticles having a functional group capable of reacting with and binding to the antibody, and discloses bovine serum albumin as an example of the blocking agent.
- JP2001-21563A discloses a specific conjugate including a water dispersible polymer particle as a carrier, in which the carrier has, on a surface thereof, a substance specifically binds to a test substance, and a blocking agent for nonspecific adsorption, and discloses bovine serum albumin as an example of the blocking agent for nonspecific adsorption.
- a fluorescence detection method by surface plasmon excitation has been known as a simple measurement method by which high sensitive measurement is possible, but the measurement accuracy was not sufficiently satisfied. That is, in order to quantitatively determining a substance to be measured with high accuracy, a simple measurement method with higher reproducibility is desired.
- An object of the present invention is to provide a kit and a method by which a quantitative determination of a substance to be measured in a biological sample can be carried out with high accuracy while avoiding the influence of an antibody such as an anti-serum albumin antibody present in blood.
- the inventors of the present invention conducted intensive studies to solve the above-described problems, and as a result, have found that the problems can be solved by quantitatively determining a substance to be measured in a biological sample by using a labeled particle that has a first binding substance capable of binding to the substance to be measured, and a first blocking agent; and a substrate that has a detection region having a second binding substance capable of binding to any one of the substance to be measured and the first binding substance, and has second blocking agent different from the first blocking agent.
- the present invention has been completed based on these findings. That is, according to the present invention, the following invention is provided.
- a kit for quantitatively determining a substance to be measured in a biological sample comprising: a labeled particle that has a first binding substance capable of binding to the substance to be measured, and a first blocking agent; and a substrate that has a detection region having a second binding substance capable of binding to any one of the substance to be measured and the first binding substance, and a second blocking agent, in which the first blocking agent and the second blocking agent are different from each other.
- globulin is an immunoglobulin other than an immunoglobulin capable of binding to the substance to be measured.
- a method for quantitatively determining a substance to be measured in a biological sample comprising: a reaction step of reacting a biological sample with a labeled particle that has a first binding substance capable of binding to the substance to be measured and has a first blocking agent; and a substance to be measured-related label information acquisition step of bringing a reaction product obtained in the reaction step into contact with a substrate that has a detection region having a second binding substance capable of binding to any one of the substance to be measured and the first binding substance and having a second blocking agent, and capturing the labeled particle on the substrate so as to acquire label information related to an amount of the substance to be measured, in which the first blocking agent and the second blocking agent are different from each other.
- the quantitative determination of the substance to be measured in the biological sample can be carried out with high accuracy.
- FIG. 1 shows a schematic view of a sensor chip provided in a kit of the present invention.
- FIG. 2 shows an exploded view of the sensor chip provided in the kit of the present invention.
- a kit for quantitatively determining a substance to be measured in a biological sample includes: a labeled particle that has a first binding substance capable of binding to the substance to be measured, and a first blocking agent; and a substrate that has a detection region having a second binding substance capable of binding to any one of the substance to be measured and the first binding substance, and a second blocking agent, in which the first blocking agent and the second blocking agent are different from each other.
- blocking agents different from each other are used as a blocking agent (first blocking agent) on the labeled particle and a blocking agent (second blocking agent) on the detection region of the substrate, and therefore it became possible to provide a kit for quantitative determination and a method for quantitative determination in which measurement accuracy is high. That is, in the present invention, because the first blocking agent and the second blocking agent are different from each other, it is possible to avoid the influence of an antibody component which may be present in the biological sample, and therefore improvement in measurement accuracy is achieved.
- bovine serum albumin (BSA) is used as the first blocking agent and the second blocking agent
- BSA bovine serum albumin
- the detection region of the substrate and the labeled particle is bound to the anti-BSA antibody, and thus accurate quantitative determination cannot be performed.
- the biological sample is not particularly limited as long as the biological sample is a sample which may contain the substance to be measured, and examples thereof include a biological sample, particularly body fluids (for example, blood, blood serum, blood plasma, cerebrospinal fluid, tear fluid, sweat, urine, pus, nasal discharge, or expectoration) of animals (for example, humans, dogs, cats, and the like), excretas (for example, feces), organs, tissues, membrana mucosa, skin, and the like.
- body fluids for example, blood, blood serum, blood plasma, cerebrospinal fluid, tear fluid, sweat, urine, pus, nasal discharge, or expectoration
- excretas for example, feces
- the substance to be measured is not particularly limited, and examples thereof include bile acids, cortisols, cholesterols, proteins, and the like.
- a bile acid is a generic term for compounds which has a cholanic acid skeleton and is a steroid derivative present in the bile of mammals, and representative examples thereof include a cholic acid, a deoxycholic acid, and a chenodeoxycholic acid.
- the main role of the bile acids is to promote the formation of micelles in the digestive tract so that dietary fat becomes likely to be absorbed.
- a bile acid which is biosynthesized in the liver is called a primary bile acid.
- some bile acids undergo microbial conversion in the intestinal tract, and a metabolite thereof is called a secondary bile acid.
- the bile acid is generally associated with glycine and taurine, and such a bile acid is called a conjugated bile acid (a bile salt).
- a rapid and simple method for measuring a concentration of serum bile acids in dogs and cats has been recognized as a high sensitive and specific examination reflecting hepatocyte functions and enterohepatic circulation.
- serum bile acids in dogs and cats which exhibit a high level of liver enzyme activity but are not accompanied with jaundice and in which clinical signs are unclear and cannot be interpreted, the usefulness of the serum bile acids has been demonstrated in order to detect hepatobiliary diseases that require clinically definite diagnosis.
- a quantitative determination of fasting and postprandial bile acids has been recommended in order to increase a diagnostic rate in diagnosis of congenital portosystemic shunt.
- Such bile acids are present as aggregates of compounds having slightly different structures, and specifically, ten types of compounds are present.
- three types of a cholic acid, a deoxycholic acid, and a chenodeoxycholic acid account for almost 100% as bile acids.
- the structures of the cholic acid, the deoxycholic acid, and the chenodeoxycholic acid are as follows.
- the first binding substance used in the present invention is a substance capable of binding to the substance to be measured.
- an antigen, an antibody, or a complex thereof can be used, but the first binding substance is not limited thereto.
- the first binding substances are preferable antibodies.
- the first binding substances are the antibodies
- the antibodies capable of binding to the substance to be measured for example, an antiserum prepared from blood serum of an animal immunized with the substance to be measured, an immunoglobulin fraction purified from an antiserum, a monoclonal antibody obtained by cell fusion using spleen cells of an animal immunized with the substance to be measured, fragments thereof [for example, F(ab′) 2 , Fab, Fab′, or Fv], and the like can be used.
- the preparation of these antibodies can be carried out by using a general method.
- an antibody modified as a case of a chimeric antibody or the like may be used, or a commercially available antibody also may be used as long as the antibody is an antibody prepared from blood serum of an animal or culture supernatant by a known method.
- an anti-bile acid antibody that is capable of binding to the bile acids (preferably, specifically recognizes the bile acids) is used. Since the bile acids include the cholic acid, the deoxycholic acid, and the chenodeoxycholic acid, in the present invention, as the first binding substance, an anti-cholic acid antibody, an anti-deoxycholic acid antibody, and an anti-chenodeoxycholic acid antibody can be produced so as to be used as the three types of antibodies.
- the anti-cholic acid antibody As a specific method for producing the anti-cholic acid antibody, the anti-deoxycholic acid antibody, and the anti-chenodeoxycholic acid antibody, a method for producing the anti-cholic acid antibody will be described below as an example.
- a cholic acid-BSA conjugate by mixing a cholic acid, bovine serum albumin (hereinafter will be abbreviated as BSA), and a condensing agent.
- BSA bovine serum albumin
- the conjugate is used as a mouse immunizing antigen and a mouse is immunized subcutaneously several times on the back thereof.
- a complete adjuvant Complete Freund's Adjuvant: CFA
- an incomplete adjuvant Incomplete Freund's Adjuvant: IFA
- the complete adjuvant is a substance that stimulates immunity and is a mixture of paraffin and ARLACEL.
- the incomplete adjuvant is an adjuvant in which killed bacteria of dead mycobacteria or Mycobacterium tuberculosis are added to the complete adjuvant so as to further enhance antigenicity.
- blood is collected from the mouse and antibody titers are measured.
- the antigen is administered intraperitoneally and the spleen is extracted several days later.
- hybrid cells only cells producing an antibody against the target antigen are selected and subjected to limiting dilution so as to proliferate only the cell line thereof. Culturing (cloning) of the cells after dilution can be carried out.
- Culturing (cloning) of the cells after dilution can be carried out.
- an anti-cortisol antibody that is capable of binding to the cortisol (preferably, specifically recognizes the cortisol) can be used.
- Production of the anti-cortisol antibody can be carried out according to the above-described method for producing an anti-cholic acid antibody.
- a particle having a label which can be generally used for immunologic response can be used.
- a fluorescent particle colored with fluorescence which can be generally used for immunologic response can be used, a particle labeled with enzymes, or the like can also be used.
- fluorescent polymer particles such as fluorescent polystyrene beads, or fluorescent glass particles such as fluorescent glass beads
- a material of the fluorescent particles include synthetic polymer powders such as a polymer using a monomer such as styrene, methacrylic acid, glycidyl (meth)acrylate, butadiene, vinyl chloride, vinyl acetate acrylate, methyl methacrylate, ethyl methacrylate, phenyl methacrylate, or butyl methacrylate, or a copolymer using two or more kinds of monomers, and a latex in which these powders are uniformly suspended is preferred.
- other examples thereof include organic polymer powders and inorganic substance powders, microorganisms, blood cells and cell membrane pieces, liposomes, and the like.
- a material of the latex include polystyrene, styrene-acrylic acid copolymer, styrene-methacrylic acid copolymer, styrene-glycidyl (meth)acrylate copolymer, styrene-styrene sulfonic acid salt copolymer, methacrylic acid polymer, acrylic acid polymer, acrylonitrile-butadiene-styrene copolymer, vinyl chloride-acrylic acid ester copolymer, polyvinyl acetate acrylate, and the like.
- a copolymer containing at least styrene as a monomer is preferable, and a copolymer of styrene and an acrylic acid or a methacrylic acid is particularly preferable.
- a method for producing the latex is not particularly limited, and the latex can be producing by any polymerization method. It is difficult to immobilize the antibody in a case where a surfactant is present in a case of antibody labeling, and therefore the production of the latex is preferably carried out by emulsion polymerization of a demulsifier, that is, emulsion polymerization without using an emulsifier such as a surfactant.
- the latex When the latex itself obtained by the polymerization is fluorescent, the latex can be used as the fluorescent latex particle as it is.
- the fluorescent latex particle can be produced by adding a fluorescent substance (such as a fluorescent dye) to the latex. That is, the fluorescent latex particle can be produced by adding the fluorescent dye to a solution of latex particles containing water and a water-soluble organic solvent and stirring the same.
- Fluorescence coloring is not particularly limited as long as the fluorescence coloring is released in a case of absorbing and exciting ultraviolet light or the like and returning to a ground state.
- the fluorescence coloring such as yellow green (excitation wavelength 505 nm/emission wavelength 515 nm, hereinafter the same applies), blue (350 to 356 nm/415 to 440 nm), red (535 to 580 nm/575 to 605 nm), orange (540 nm/560 nm), red orange (565 nm/580 nm), crimson (625 nm/645 nm), dark red (660 nm/680 nm), and the like, may be used.
- These fluorescent particles emitting fluorescence are available from, for example, Thermo Fisher and are commercially available on the market under the trade name of FluoSpheres (registered trademark) of the same company.
- An average particle diameter of the labeled particles varies depending on the material of the particles, a concentration range for the quantitative determination of the substance to be measured, a measuring instrument, and the like, but is preferably within the range of 0.001 to 10 ⁇ m (more preferably 0.001 to 1 ⁇ m).
- the average particle diameter of the labeled particles can be measured with a commercially available particle size distribution meter or the like.
- a method for measuring the particle size distribution optical microscopy, confocal laser microscopy, electron microscopy, atomic force microscopy, static light scattering method, laser diffraction method, dynamic light scattering method, centrifugal sedimentation method, electric pulse measurement method, chromatography method, ultrasonic attenuation method, and the like are known, and devices corresponding to the respective principles are commercially available.
- the dynamic light scattering method it is preferable to use the dynamic light scattering method in the present invention.
- a method for immobilizing the first binding substance on the labeled particles is described in protocols and the like attached to, for example, JP2000-206115A and FluoSpheres (registered trademark) polystyrene microsphere F8813 manufactured by Thermo Fisher, and any known methods for preparing a reagent for immunoagglutination reaction can be used.
- any principle of immobilizing an antibody as a binding substance to particles any principle of physical adsorption and chemical bond by covalent bond can be adopted.
- blocking agent which covers the surface of the particle not coated with the antibody after the antibody is immobilized on the particles
- first blocking agent for example, it is possible to use a commercially available blocking agent for immunologic response, which contains the above-described substances or substances having the same properties as the above-described substance, which are known substances such as albumin (BSA and the like), skim milk, casein, soy-derived components, fish-derived components, polyethylene glycol, and the like.
- These blocking agents can also be subjected to a pretreatment such as partial denaturation by heat, acid, alkali, or the like, as necessary.
- first blocking agent antibodies (globulin) that do not bind to the substance to be measured, proteins not to be used in the test area (Protein A, Protein G), or the like can be used.
- a blocking agent such as components not involved in antigen-antibody reaction, preferably proteins, more preferably globulin, albumin, BLOCK ACE (registered trademark), skim milk, and casein.
- stabilizers can be added as necessary.
- the stabilizer is not particularly limited as long as the stabilizer stabilizes antigens and antibodies, such as synthetic polymers such as sucrose and polysaccharides, or natural polymers.
- Commercially available stabilizers such as Immunoassay Stabilizer (Advanced Biotechnologies Inc. (ABI)), and the like can also be used.
- the labeled particles having the first binding substance are included in the kit of the present invention, and an aspect in which the fluorescent particles are contained in the container which is a part of the kit, for example, in a cup, is preferable.
- the biological sample is injected into the container containing the labeled particles, mixed, and stirred, whereby the first binding substance and the substance to be measured in the biological sample can bind to each other.
- a substrate in this case, it is preferable to use a substrate having a metal film on a surface thereof.
- a metal constituting the metal film is not particularly limited as long as it is a metal by which surface plasmon resonance can occur.
- Preferable examples thereof include free electron metals such as gold, silver, copper, aluminum, or platinum, and gold is particularly preferable.
- the detection region to be described below is on a gold film. These metals can be used alone or in combination.
- an intermediacy layer made of chromium or the like may be provided between the substrate and a layer formed of the metal.
- Any thickness of the metal film may be used, but is preferably, for example, 1 nm to 500 nm, and particularly preferably 10 nm to 200 nm. In a case where the thickness exceeds 500 nm, the surface plasmon phenomenon of a medium cannot be sufficiently detected.
- the thickness of the intermediacy layer is preferably 0.1 nm to 10 nm.
- the formation of the metal film may be carried out by a general method and can be carried out by, for example, a sputtering method, a vapor deposition method, an ion plating method, an electroplating method, an electroless plating method, or the like, but in order to improve the adhesiveness of the metal film by providing a mix layer of the substrate material and the metal film, it is preferable to produce the metal film by the sputtering method.
- a thickness of the mix layer of the substrate material and the metal film is not particularly limited as long as sufficient adhesiveness can be secured, but is preferably 10 nm or less.
- the metal film is preferably disposed on the substrate.
- the term “disposed on the substrate” means not only that the metal film is disposed in direct contact with the substrate, but also that the metal film is disposed via other layers without in direct contact with the substrate.
- optical glass such as BK7 (borosilicate glass) which is one of general optical glasses, or synthetic resin, specifically, polymethyl methacrylate, polyethylene terephthalate, polycarbonate, cycloolefin polymer, or the like which is transparent to laser light can be used. It is desirable that such a substrate has a material which does not exhibit anisotropy with respect to polarized light and has excellent workability.
- the substrate for detecting SPF there is a substrate obtained by vapor-depositing a gold film on polymethyl methacrylate (PMMA), and the like.
- the substrate has a detection region having a second binding substance capable of binding to any one of the substance to be measured and the first binding substance.
- the second binding substance is a substance capable of binding to the substance to be measured or is a substance capable of binding to the first binding substance.
- the quantitative determination is carried out by a sandwich assay method
- the substance capable of binding to the substance to be measured can be used as the second binding substance.
- the quantitative determination is carried out by a competitive method
- the substance capable of binding to the first binding substance can be used as the second binding substance.
- it is preferable to carry out the quantitative determination by a competitive method and it is preferable to use the substance capable of binding to the first binding substance as the second binding substance.
- the second binding substance is not particularly limited, but preferable examples thereof include an antigen, an antibody, or a complex thereof.
- the second binding substance is preferably an antigen, and the substance to be measured (which is the substance capable of binding to the first binding substances) is particularly preferably used as the second binding substance.
- the second binding substance is preferably a conjugate of the substance to be measured and a carrier.
- carrier means a substance to which a plurality of molecules of the substance to be measured can bind.
- the carrier include proteins and the like, and specific examples include bovine serum albumin and the like.
- the second binding substance includes a cholic acid and/or a cholic acid-albumin conjugate, a deoxycholic acid and/or a deoxycholic acid-albumin conjugate, and a chenodeoxycholic acid and/or a chenodeoxycholic acid-albumin conjugate.
- the second binding substance is preferably a cortisol-albumin conjugate.
- a method for immobilizing the second binding substance on the substrate is described in, for example, Tech Notes Vol. 2-12 and the like provided by Nunc, and any known methods for preparing a general ELISA (Enzyme-Linked ImmunoSorbent Assay) reagent can be used.
- surface modification may be performed by disposing a self-assembled monolayer (self-assembled monolayer: SAM) or the like on the substrate, and any method of a method using physical adsorption and a method using chemical bonds by covalent bonds can be adopted as a method for immobilizing the second binding substance on the substrate.
- blocking agent which covers the surface of the substrate not coated with the second binding substance after the second binding substance is immobilized on the substrate (second blocking agent)
- second blocking agent a commercially available blocking agent for immunologic response, which contains the above-described substances or substances having the same properties as the above-described substance, which are known substances such as bovine serum albumin (BSA), globulin, skim milk, casein, soy-derived components, fish-derived components, polyethylene glycol, and the like.
- BSA bovine serum albumin
- globulin globulin
- skim milk casein
- soy-derived components fish-derived components
- polyethylene glycol polyethylene glycol
- a test area for detecting the presence or absence of the substance to be measured in the biological sample can be provided on the substrate.
- this test area it is possible to quantitatively determine antigens by, for example, capturing the antigens which are the substances to be measured and detecting and quantitatively determining an amount of label bound to the antigens.
- test area of the substrate it is preferable to provide sites reacting with all the binding substances (for example, antibodies) present on the labeled particles.
- binding substances for example, antibodies
- an aspect in which antigens present in the biological sample are provided on the test area of the substrate is preferable. In this case, it is possible to produce the test area by reacting the antigens with BSA in the presence of a condensing agent to produce an antigen-BSA conjugate and adsorbing this conjugate on the test area.
- the antigen-BSA conjugate which is the substance to be measured is dissolved in a buffer solution, spotted onto the substrate, and left alone for a certain period of time, and then the supernatant is aspirated and bound to the test area on the substrate by a method such as drying.
- a control area is provided on the substrate and information of the test area is standardized by information of the control area, and therefore it is possible to suppress environment dependency to a significantly low level.
- the control area is designed such that the control area can be combined with all the labels irrespective of an amount of the substances to be measured which are present in the biological sample to be used.
- an antibody which interacts with all the antibodies present on the labeled particles, is provided.
- an anti-mouse antibody is preferable as long as an anti-mouse antibody has a function of recognizing the binding substances (for example, antibodies) present on the labeled particles and is derived from a mouse, and in a case where the antibody on the labeled particles is derived from a goat, an anti-goat antibody is preferable. It is possible that these antibodies on the control area are dissolved in a buffer solution, spotted onto the substrate, and left alone for a certain period of time, and then the supernatant is aspirated and bound to the substrate by a method such as drying.
- blocking with BSA is used for suppressing nonspecific adsorption to a solid surface (for example, the surface of the labeled particles, a gold film surface of the substrate), but in a case where an anti-BSA antibody reacting with BSA is present in a specific biological sample, BSA on the labeled particles reacts with BSA on the substrate so as to be crosslinked, and high value dissociation occurs in some cases.
- a solid surface for example, the surface of the labeled particles, a gold film surface of the substrate
- the first blocking agent and the second blocking agent are different from each other, and therefore the above-described problem is solved.
- the first blocking agent and the second blocking agent are preferably proteins different from each other.
- Specific examples of the first blocking agents and the second blocking agents are as described in the present specification.
- the first blocking agent is one of albumins and globulins
- the second blocking agent is another one of albumins and globulins.
- the first blocking agent is globulin (more preferably, an immunoglobulin other than an immunoglobulin capable of binding to the substances to be measured)
- the second blocking agent is albumin (more preferably, bovine serum albumin).
- an antiserum prepared from blood serum of an animal immunized with an antigen different from the substances to be measured, an immunoglobulin fraction purified from an antiserum, a monoclonal antibody obtained by cell fusion using spleen cells of an animal immunized with the substances to be measured, fragments thereof [for example, F(ab′) 2 , Fab, Fab′, or Fv], and the like can be used.
- the preparation of these antibodies can be carried out by using a general method.
- an antibody modified as a case of a chimeric antibody or the like may be used, or a commercially available antibody also may be used as long as the antibody is an antibody prepared from blood serum of an animal or culture supernatant by a known method.
- an aspect in which an anti-CRP (C-reactive protein) antibody is used as the first blocking agent is particularly preferable.
- the antibody can be used regardless of animal species or subclass thereof.
- the antibody that can be used in the present invention is an antibody derived from an organism in which an immunologic response can occur, such as mouse, rat, hamster, goat, rabbit, sheep, cow, and chicken.
- specific examples thereof include mouse IgG, mouse IgM, rat IgG, rat IgM, hamster IgG, hamster IgM, rabbit IgG, rabbit IgM, goat IgG, goat IgM, sheep IgG, sheep IgM, bovine IgG, bovine IgM, avian IgY, and the like, and both polyclonal and monoclonal antibodies can be used.
- Fragmented antibodies are molecules derived from intact antibodies having at least one antigen binding site, and specific examples thereof include Fab, F(ab′) 2 and the like. These fragmented antibodies are molecules obtained by enzymatic or chemical treatment or using genetic engineering techniques.
- the kit of the present invention is used for the method for measuring the substances to be measured, is a kit for diagnosis of the bile acid measurement in a case where the substances to be measured are the bile acids, and is a kit for diagnosis of the cortisol measurement in a case where the substances to be measured are cortisol.
- the sensor chip including a substrate on which the second binding substance is immobilized; and a member for retaining the labeled particles such as fluorescent particle, is provided, but various devices or instruments used for measuring the substances to be measured such as surface plasmon excitation devices and fluorescence measurement devices may be provided.
- a sample containing substances to be measured of known amounts, an instruction manual, and the like may be included.
- a method for quantitatively determining substances to be measured in a biological sample includes a reaction step of reacting a biological sample with a labeled particle that has a first binding substance capable of binding to the substance to be measured and has a first blocking agent; and a substance to be measured-related label information acquisition step of bringing a reaction product obtained in the reaction step into contact with a substrate that has a detection region having a second binding substance capable of binding to any one of the substance to be measured and the first binding substance and having a second blocking agent, and capturing the labeled particles on the substrate so as to acquire label information related to an amount of the substance to be measured, in which the first blocking agent and the second blocking agent are different from each other.
- the substances to be measured are quantitatively determined by the substance to be measured-related label information acquisition step in which label information related to an amount of the substances to be measured is acquired.
- the quantitative determination in the present invention is interpreted as the broadest concept as long the quantitative determination is measurement of an amount of the substances to be measured. Specific aspects of the measurement method include the competitive method and the sandwich method, but the competitive method is preferable.
- the biological sample containing the bile acid is contacted with an anti-bile acid antibody-labeled fluorescent particle.
- an antigen-antibody reaction occurs on the substrate by the anti-bile acid antibody-labeled fluorescent particle and the bile acid on the substrate (that is, the bile acid in the bile acid-albumin conjugate).
- an antigen-antibody reaction occurs between the bile acid in the biological sample and the anti-bile acid antibody-labeled fluorescent particle, and an antigen-antibody reaction is inhibited between the bile acid (for example, the bile acid in the bile acid-albumin conjugate) on the substrate and the anti-bile acid antibody-labeled fluorescent particle.
- the bile acid for example, the bile acid in the bile acid-albumin conjugate
- a degree of formation of immune complexes on the substrate that is, a complex of the anti-bile acid antibody-labeled fluorescent particle and the bile acid in the bile acids-albumin conjugate on the substrate
- fluorescence intensity it is possible to measure a concentration of the bile acid in the biological sample, and the like.
- a measurement form of fluorescence in the competitive method it is possible to adopt any one of plate reader measurement and flow measurement, and for example, the measurement can be carried out by the following method.
- a plurality of samples with known amounts of the bile acid differing in bile acid concentration is prepared in advance, and this sample is mixed with the anti-bile acid antibody-labeled fluorescent particles in advance.
- This mixed solution is brought into contact with a region on which the bile acid-albumin conjugate is immobilized.
- a fluorescent signal from the region on which the bile acid-albumin conjugate is immobilized is measured as a plurality of fluorescent signals while the mixed solution is in contact with the conjugate at specific time intervals.
- a time change (inclination) of the amount of fluorescence is obtained at each bile acid concentration.
- a relational expression of the bile acid concentration with respect to the time change in the fluorescence amount is acquired by using an appropriate fitting method such as a least squares method or the like. Based on the relational expression thus obtained, the amount of bile acid contained in the biological sample can be quantitatively determined by using the result of the time change of the amount of fluorescence using the biological sample to be examined.
- the quantitative determination of the amount of bile acid is preferably carried out in a short period of time. Specifically, the quantitative determination is preferably carried out within 10 minutes, more preferably within 8 minutes, and even more preferably within 6 minutes.
- the sample and the anti-bile acid antibody-labeled fluorescent particle are brought into contact with the detection region to which the bile acid-albumin conjugate is immobilized, and then a time for converting the amount of bile acid contained in the biological sample is obtained based on the result of the time change of the fluorescence amount using the biological sample to be examined, and a time for the quantitative determination preferably includes this time for conversion.
- the sandwich method is not particularly limited, and for example, the substances to be measured can be measured by the following procedure.
- a biological sample that may contain the substances to be measured and the fluorescent particle having the first binding substance capable of binding to the substances to be measured are brought into contact with each other on the substrate.
- a binding reaction such as an antigen-antibody reaction
- the substances to be measured is present in the biological sample, a binding reaction (such as an antigen-antibody reaction) occurs between the substances to be measured, the fluorescent particle, and the substrate.
- an immune complex composed of the second binding substance bound to the substrate, the substances to be measured, and the fluorescent particles having the first binding substance is formed.
- the fluorescent particle having the first binding substance in which the immune complex has not been formed, is removed and washed. Subsequently, the concentration of substances to be measured or the like can be measured by detecting a degree of immune complex formation as fluorescence intensity.
- the fluorescence intensity and the concentration of substances to be measured have a positive correlation.
- a mixed solution obtained by mixing the biological sample that may contain the substances to be measured and the labeled particles having the first binding substance can be applied on the substrate and developed in a flow passage.
- the flow passage is not particularly limited as long as it is a passage that allows the biological sample and the labeled particles having the first binding substances to flow down to the detection region.
- Preferable aspects of the flow passage include a spotting port for spotting the biological sample solution containing the labeled particles having the first binding substance, the metal film as the detection region, and a flow passage beyond the metal film.
- the biological sample has a structure capable of passing over the metal film.
- a suction port can be provided on the side opposite to the spotting port with respect to the metal film.
- a method for detecting labels such as fluorescence in the present invention is not particularly limited, and examples thereof include a device capable of detecting fluorescence intensity. Specifically, it is preferable to detect fluorescence intensity using a microplate reader, or biosensor for performing fluorescence detection (SPF) by surface plasmon excitation.
- the label information related to an amount of the substances to be measured is preferably acquired from fluorescence detection by surface plasmon resonance.
- the form of measurement of fluorescence may be plate reader measurement or flow measurement.
- the fluorescence detection method (SPF method) by surface plasmon excitation can perform the measurement with higher sensitivity than the fluorescence detection method (epifluorescence method) by epi-excitation.
- a surface plasmon fluorescence (SPF) biosensor for example, it is possible to use a sensor, which is described in JP2008-249361A, the sensor including an optical waveguide formed from a material that transmits excitation light of a predetermined wavelength, a metal film formed on one surface of this optical waveguide, a light source for generating a light beam, an optical system that allows the light beam to pass through the optical waveguide and causes the light beam to enter the interface between the optical waveguide and the metal film at an incident angle that generates surface plasmons, and a fluorescence detection means for detecting the fluorescence generated by being excited by the above-described evanescent wave enhanced by the surface plasmon.
- the sensor including an optical waveguide formed from a material that transmits excitation light of a predetermined wavelength, a metal film formed on one surface of this optical waveguide, a light source for generating a light beam, an optical system that allows the light beam to pass through the optical waveguide and causes the light beam to enter the interface between the optical
- the fluorescence detection (SPF) system by surface plasmon excitation using the fluorescent particles of the present invention is a preferably an assay method for detecting fluorescence from the fluorescent substance dependent on the amount of substances to be measured immobilized on the metal film on the substrate, which is the method different from a so-called latex agglutination method in which a change in optical transparency is detected as, for example, turbidity due to progress of reaction in a solution.
- a so-called latex agglutination method in which a change in optical transparency is detected as, for example, turbidity due to progress of reaction in a solution.
- an antibody-sensitized latex in the latex reagent and the antigen in the biological sample bind and aggregate by an antibody reaction.
- the latex agglutination method is a method in which the agglomerate increases with time, and an antigen concentration is quantitatively determined from a change in absorbance per unit time obtained by irradiating the aggregate with near infrared light.
- an antigen concentration is quantitatively determined from a change in absorbance per unit time obtained by irradiating the aggregate with near infrared light.
- the method of the present invention may a method further including a labeled particle-related label information acquisition step of acquiring label information related to an amount of the labeled particles; and a standardization step of standardizing the label information acquired in the substance to be measured-related label information acquisition step of acquiring label information related to an amount of the substances to be measured, by the label information acquired in the labeled particle-related label information acquisition step.
- a step of measuring the fluorescence intensity due to the surface plasmon generated on the detection region is the substance to be measured-related label information acquisition step of acquiring the label information related to an amount of the substances to be measured, and a step of measuring the fluorescence intensity due to the surface plasmon generated on the reference region is the labeled particle-related label information acquisition step.
- a step in which an increase rate of the fluorescence intensity obtained in the two steps in unit time is obtained as a change rate of a fluorescence signal value, and a change rate of a signal value of the detection region is divided by a change rate of a signal value of the reference region, is the standardization step.
- DMF super dehydrated dimethylformamide
- NHS sodium hydroxysuccinimide
- EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
- This actively esterified cholic acid was dropwise added to and reacted with an aqueous solution of a 65 mL of a phosphate buffer solution (hereinafter, will be referred to as PBS, manufactured by Wako Pure Chemical Industries, Ltd.) in which 322 mg of bovine serum albumin (hereinafter, will be referred to as BSA, manufactured by Wako Pure Chemical Industries, Ltd.) as one type of albumin was dissolved.
- PBS phosphate buffer solution
- BSA bovine serum albumin
- the reaction solution was purified by dialysis using 1 L of a solution in which a ratio of acetonitrile (hereinafter, will be referred to ACN, manufactured by Wako Pure Chemical Industries, Ltd.)/water was 1/3. Finally, freeze-drying was carried out, and therefore a white solid was obtained.
- deoxycholic acid manufactured by Wako Pure Chemical Industries, Ltd.
- 67 mg of NHS, and 110 mg of EDC were added to 1.2 mL of super dehydrated DMF so as to be mixed, and therefore the deoxycholic acid was actively esterified.
- This actively esterified deoxycholic acid was added dropwise to and reacted with an aqueous solution of 65 mL of PBS in which 322 mg of BSA was dissolved.
- the reaction solution was purified by dialysis using 1 L of a solution in which a ratio of ACN/water was 1/3. Finally, freeze-drying was carried out, and therefore a white solid was obtained.
- the conjugates prepared in (1-1) to (1-3) were dissolved in a solution in which a ratio of 0.1% by mass of trifluoroacetic acid (TFA):ACN is 2:1, and a concentration was adjusted to 1 mg/mL.
- the cholic acid-BSA conjugate was used as the immunogen for mouse immunization.
- the cholic acid-BSA conjugate was subcutaneously administered to a mouse so as to carry out the immunization by an initial immunization with an amount of 100 ⁇ g/mouse, and a second and subsequent immunizations with an amount of 50 ⁇ g/mouse.
- an emulsion mixed with complete adjuvant (CFA) was administered first, and for the second to fourth immunizations, an emulsion mixed with incomplete adjuvant (IFA) was administered.
- CFA complete adjuvant
- IFA incomplete adjuvant
- the immunizations were carried out 4 times at 2-week interval. Separately, blood was collected the following week of the third and fourth immunizations, and antibody titers were measured by ELISA measurement using 100 ⁇ L of the collected serum.
- the antibody titers were the target values, and the conjugate as an antigen was diluted and dissolved in 1 mL of a phosphate buffer solution (PBS, manufactured by Wako Pure Chemical Industries, Ltd., pH 7.1 to 7.3) and the resultant was intraperitoneally administered to a mouse, while taking the immunization two weeks after the fourth immunization as a final immunization.
- PBS phosphate buffer solution
- the spleen of the mouse was extracted 3 days after the administration.
- Spleen cells extracted from the mouse and mutant myeloma cell lines (myeloma: P3-X63-Ag8-U1) were mixed at a ratio of 7:1 of the number of cells, and then polyethylene glycol (PEG) was added thereto. After centrifugation, the cells were suspended in a medium (RPMI-1640 (Roswell Park Memorial Institute Medium)+10% by mass fetal bovine serum (FBS)). The suspended spleen cells were seeded on a 96-well plate so that the number of cells was 1.0 ⁇ 10 5 (cell/well).
- RPMI-1640 Roswell Park Memorial Institute Medium
- FBS mass fetal bovine serum
- HAT medium hyperxanthine-aminopterin-thymidine medium
- HAT medium hyperxanthine-aminopterin-thymidine medium
- the cholic acid-BSA conjugate which is an antigen for measurement, was diluted with PBS to a concentration of 500 ng/mL, added to a cup of ELISA and left alone, and then immobilized at the bottom of the cup so as to remove the supernatant.
- An anti-mouse IgG HRP-labeled antibody was used as a secondary antibody against the antibody produced by the spleen cells of the measurement target. IgG shows immunoglobulin G and HRP shows horseradish peroxidase.
- the cells in each vial were subjected to limiting dilution using basal medium RPMI 1640 containing 10% by mass of FBS, and therefore dilutions were prepared.
- basal medium RPMI 1640 containing 10% by mass of FBS basal medium RPMI 1640 containing 10% by mass of FBS, and therefore dilutions were prepared.
- One drop of each dilution was pipetted and added into each well of six 96-well plates. Each well was observed under a microscope, and it was confirmed that the cells in each well were single cells.
- culture supernatants of the proliferated hybridomas were screened by ELISA of the antibody assay system in the same manner as described above.
- the top 10 wells with high ELISA signals were selected and hybridoma preparation was completed.
- An Isotyping kit (manufactured by Roche) was used to determine the subclass of the obtained antibody.
- an anti-cholic acid antibody-1 In the same manner, cells selected from the 10 wells were subjected to ELISA screening, and antibodies were produced by a mouse ascites method (using two mice) with respect to the top cells of the wells having a highest signal. The obtained antibody is referred to as an anti-cholic acid antibody-1.
- the preparation of a deoxycholic acid antibody and a chenodeoxycholic acid antibody was carried out in the same manner as above.
- the obtained antibodies are referred to as an anti-deoxycholic acid antibody-1 and an anti-chenodeoxycholic acid antibody-1, respectively.
- a mouse-derived globulin (LAMPIRE Biological Laboratories, Catalog No. 7404302, Mouse Gamma Globulin Salt Fractionation, 500 mg) was prepared, and the immunization of goats (subcutaneous immunization) was carried out four times at two-week intervals by using the method in which the emulsion mixed with complete Freund's adjuvant (CFA) was administered first and for the second to fourth immunizations, the emulsion mixed with incomplete adjuvant (IFA) was administered. Thereafter, ELISA measurement was carried out to confirm an increase in antibody titers, followed by performing of total blood collection, and antiserum was obtained by centrifugation. Thereafter, purification was carried out using Protein A column (Pierce Protein A Columns, catalog No. 20356, manufactured by Thermo scientific Co., Ltd.), and therefore a desired anti-mouse antibody was obtained.
- CFA complete Freund's adjuvant
- IFA incomplete adjuvant
- rCRP antigen Recombinant CRP: manufactured by Oriental Yeast Co., Ltd., product number 47191000, 5 mg
- CFA complete adjuvant
- IFA incomplete adjuvant
- ELISA measurement was carried out to confirm an increase in antibody titers, followed by performing of total blood collection, and antiserum was obtained by centrifugation.
- purification was carried out using Protein A column (Pierce Protein A Columns, catalog No. 20356, manufactured by Thermo scientific Co., Ltd.), and therefore a desired anti-CRP antibody-1 was obtained.
- Fluorescent particles blocked with the anti-CRP antibody-1 were prepared as follows.
- aqueous solution with EDC of 10 mg/mL was added thereto, and the mixture was stirred at room temperature for 1.5 hours.
- the centrifugation (15,000 rpm, 4° C., 15 minutes) was carried out again so as to remove the supernatant, then 750 ⁇ L PBS (pH 7.4) was added thereto so as to redisperse the fluorescent latex particles, and therefore a solution with the fluorescent particles 1 of 1% by mass to which three types of the anti-bile acid antibodies and the anti-CRP antibody bound, was prepared.
- Fluorescent particles blocked with BSA were prepared as follows.
- aqueous solution with EDC of 10 mg/mL was added thereto, and the mixture was stirred at room temperature for 1.5 hours.
- the supernatant was removed, 750 ⁇ L PBS solution (pH 7.4) was added, and fluorescent latex particles were redispersed with an ultrasonic washer.
- the centrifugation (15,000 rpm, 4° C., 15 minutes) was carried out again so as to remove the supernatant, then 750 ⁇ L PBS (pH 7.4) containing BSA of 1% by mass was added thereto so as to redisperse the fluorescent latex particles, and therefore a solution with the fluorescent particles 2 of 1% by mass blocked with BSA was prepared.
- PMMA substrate (ACRYPET (registered trademark) VH, manufactured by Mitsubishi Rayon Co., Ltd.) was prepared.
- a magnetron sputtering method a gold film with a thickness of 45 nm was produced on one side of two regions of a detection region and a reference region so that a width became 4 mm and a length became 3 mm, and was used as a chip constituting the substrate.
- a solution (concentration: 50 ⁇ g/mL in 50 mmol/L MES buffer solution, pH 6, 150 mmol/L NaCl) containing the conjugate-1, the conjugate-2, and the conjugate-3 by a content ratio (mass ratio 1:1:1), and a solution containing a blocking agent as BSA (150 mg) were spotted on the gold film surface of the detection region of the chip and dried, and therefore a plurality of substrates 1 on which the three types of the conjugates were immobilized were produced.
- the solution (concentration: 50 ⁇ g/mL in 50 mmol/L MES buffer solution, pH 6, 150 mmol/L NaCl) containing the anti-mouse antibody produced in (4) was spotted on the reference region of each substrate and dried. Furthermore, in the same manner as above, a substrate using the anti-CRP antibody-1 (150 mg) as a blocking agent was produced.
- the substrates were repeatedly washed 3 times using 300 ⁇ L of a cleaning solution prepared in advance (PBS (pH 7.4) containing TWEEN 20 (POLYOXYETHYLENE (20) SORBITAN MONOLAURATE manufactured by Wako Pure Chemical Industries, Ltd.) of 0.05% by mass).
- PBS pH 7.4
- TWEEN 20 POLYOXYETHYLENE (20) SORBITAN MONOLAURATE manufactured by Wako Pure Chemical Industries, Ltd.
- FIGS. 1 and 2 are schematic views of the sensor chip.
- FIG. 1 is the schematic view of a sensor chip 1
- FIG. 2 is an exploded view of the sensor chip 1 .
- the sensor chip 1 is configured of an upper member 2 , an intermediate member 3 , and a substrate 4 .
- the upper member 2 has a first container 5 and a second container 6 .
- the first container 5 and the second container 6 are collectively referred to as a container group 7 .
- a flow passage 10 is formed in the substrate 4 , and a detection region 8 and a reference region 9 are formed on the flow passage 10 .
- the increase rate of fluorescence intensity in unit time of each of the detection region and the reference region obtained in each substrate was obtained as a fluorescence signal value, and a signal value of the detection region was divided by a signal value of the reference region so as to carry out the standardization.
- a sample with a concentration of bile acids of 0 was prepared, and the fluorescence signal value was standardized in the same manner, and the signal value from the sample not containing bile acids was standardized.
- Serums 1 to 4 from dogs were obtained from Kitayama Labes Co., Ltd., experiments were carried out with a combination of fluorescent particles and a substrate as shown in Table 3, and therefore measurement values of bile acids were obtained by using the calibration curve created in (11). With respect to the above serums 1 to 4, the measurement values of bile acids were determined using the large machine.
- cortisol was enaminated and reacted with a hydroxylamine derivative, and therefore synthesis of an oxime derivative-1 of cortisol was carried out.
- pyrrolidine was added dropwise to a methanol suspension of cortisol (1 g), and the mixture was stirred at room temperature for 5 minutes. Enamine was generated in the reaction system, and the solution turned red. Thereafter, another equivalent of pyrrolidine and a hydroxylamine derivative (NH 2 —O—CH 2 —COOH) (0.35 g) were added so as to decolorize the solution, and the mixture was stirred at reaction temperature of 55° C. and oximated. The reaction proceeded smoothly, and therefore the oxime derivative-1 (1.1 g: 84%) of cortisol was obtained.
- a cortisol-BSA conjugate-1 was prepared by the following method using the oxime derivative-1 of cortisol synthesized as above.
- 1 ⁇ l of this solution and 4 ⁇ l of matrix (sinapinic acid: SA) were mixed and 1 ⁇ L ⁇ 4 times were spotted on a gold plate.
- the cortisol-BSA conjugate-1 As an antigen for immunization, the cortisol-BSA conjugate-1 was used.
- the cortisol-BSA conjugate-1 was used as a mouse immunizing antigen, and the conjugate was subcutaneously injected into the back of the mouse several times with an amount of 100 ⁇ g/mouse for a first immunization, and with an amount of 50 ⁇ g/mouse for second and subsequent immunizations.
- an emulsion mixed with complete adjuvant (CFA) was administered first, and for the second to fourth immunizations, an emulsion mixed with incomplete adjuvant (IFA) was administered.
- CFA complete adjuvant
- IFA incomplete adjuvant
- Spleen cells extracted from the mouse and mutant myeloma cell lines (myeloma: P3-X63-Ag8-U1) were mixed at a ratio of 7:1, and then polyethylene glycol (PEG) was added thereto. After centrifugation, the cells were suspended in a medium (RPMI-1640+10% by mass (FBS)). The suspended spleen cells were seeded on a 96-well plate so that the number of cells was 1.0 ⁇ 10 5 (cell/well). On the next day, HAT medium was added thereto, and culture supernatants of the proliferated hybridomas were screened by ELISA of the antibody assay system.
- RPMI-1640+10% by mass (FBS) RPMI-1640+10% by mass
- An antigen for measurement was diluted with PBS solution to have a concentration of 500 ng/mL, added to a cup of ELISA and left alone, and then immobilized at the bottom of the cup so as to remove the supernatant.
- An anti-mouse IgG HRPP (horseradish peroxidase)-labeled antibody was used as a secondary antibody against the antibody produced by the spleen cells of the measurement target.
- Wells positive from the results of ELISA were cultured using a 24-well plate, and 1 mL of each culture supernatant was collected. Secondary screening was performed again by the same antibody assay system ELISA. In the same well at the time of cell fusion, the top 6 wells having high ELISA signals were selected and put in a vial.
- the cells in each vial were subjected to limiting dilution using a basal medium RPMI 1640 (Roswell Park Memorial Institute Medium) containing 10% by mass of fetal bovine serum (FBS), each one drop was added to each well of six 96-well plates with a pipette, and each well was observed under a microscope, and it was confirmed that the cells in each well were single cells.
- culture supernatants of the proliferated hybridomas were screened by ELISA of the antibody assay system in the same manner as described above. The top 10 wells with high ELISA signals were selected and hybridoma preparation was completed.
- An Isotyping kit manufactured by Roche was used to determine the subclass of the obtained antibody.
- cells selected from the 15 wells were subjected to ELISA screening, and antibodies were produced by a mouse ascites method (using two mice) with respect to the top cells of the wells having a highest signal.
- the subclass of the antibodies prepared above and an antibody production amount are shown in Table 5.
- a mouse-derived globulin (LAMPIRE Biological Laboratories, Catalog No. 7404302, Mouse Gamma Globulin Salt Fractionation, 500 mg) was prepared, and the immunization of rabbits (subcutaneous immunization) was carried out four times at two-week intervals by using the method in which the emulsion mixed with complete adjuvant (CFA) was administered first and for the second to fourth immunizations, the emulsion mixed with incomplete adjuvant (IFA) was administered. Thereafter, ELISA measurement was carried out to confirm an increase in antibody titers, followed by performing of total blood collection, and antiserum was obtained by centrifugation. Thereafter, purification was carried out using Protein A column (Pierce Protein A Columns, catalog No. 20356, manufactured by Thermo scientific Co., Ltd.), and therefore a desired anti-mouse antibody-1 was obtained.
- CFA complete adjuvant
- IFA incomplete adjuvant
- rCRP antigen Recombinant CRP: manufactured by Oriental Yeast Co., Ltd., product number 47191000, 5 mg
- CFA complete adjuvant
- IFA incomplete adjuvant
- ELISA measurement was carried out to confirm an increase in antibody titers, followed by performing of total blood collection, and antiserum was obtained by centrifugation.
- purification was carried out using Protein A column (Pierce Protein A Columns, catalog No. 20356, manufactured by Thermo scientific Co., Ltd.), and therefore a desired anti-CRP antibody-1 was obtained.
- Fluorescent particles blocked with an anti-CRP antibody-1 were prepared as follows.
- aqueous solution with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) of 10 mg/mL was added and the mixture was stirred at room temperature for 1.5 hours.
- 37.5 ⁇ L aqueous solution with Glycine of 2 mol/L (manufactured by Wako Pure Chemical Industries, Ltd.) was added thereto and stirred for 15 minutes, followed by centrifugation (15,000 rpm, 4° C., 15 minutes) so as to precipitate fluorescent latex particles. Thereafter, the supernatant was removed, 750 ⁇ L PBS solution (pH 7.4) was added, and fluorescent latex particles were redispersed with an ultrasonic washer.
- Fluorescent particles blocked with BSA which were used as comparative examples, were prepared as follows.
- PMMA substrate (ACRYPET VH, manufactured by Mitsubishi Rayon Co., Ltd.) was prepared, and by a magnetron sputtering method, a gold film with a thickness of 45 nm was produced on one side of two regions of a detection region and a reference region so that a width became 4 mm and a length became 3 mm, and therefore a chip constituting the substrate was produced.
- a solution containing the cortisol-BSA conjugate-1 prepared in (2) and a blocking agent as BSA (2 mg) (concentration: 50 ⁇ g/mL in 50 mM MES buffer solution, pH 6, 150 mM NaCl) were spotted on the gold film surface of the detection region of the chip and dried, and therefore a plurality of substrates 1 were produced.
- the solution (concentration: 50 ⁇ g/mL in 50 mM MES buffer solution, pH 6, 150 mM NaCl) containing the anti-mouse antibody-1 produced in (5) was spotted on the reference region of each substrate and dried. Furthermore, in the same manner as above, a substrate using the anti-CRP antibody-1 (2 mg) as a blocking agent was produced.
- FIGS. 1 and 2 are schematic views of the sensor chip.
- the increase rate of fluorescence intensity in unit time of each of the detection region and the reference region obtained in each substrate was obtained as a fluorescence signal value, and a signal value of the detection region was divided by a signal value of the reference region so as to carry out the standardization.
- a sample with a concentration of cortisol of 0 was prepared, and the fluorescence signal value was standardized in the same manner, and the signal value from the sample not containing cortisol was standardized.
- Serums 1 to 8 of dogs were obtained as samples from Kitayama Labes Co., Ltd. so as to carry out experiments with a combination of fluorescent particles and a substrate as shown in Table 4, and the measurement values of cortisol obtained using the calibration curve obtained in (11) and the measurement values of cortisol obtained by using a large machine were obtained.
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Inorganic Chemistry (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016037300 | 2016-02-29 | ||
JP2016-037300 | 2016-02-29 | ||
PCT/JP2017/007744 WO2017150516A1 (ja) | 2016-02-29 | 2017-02-28 | 生体試料中の測定対象物質を定量するためのキット及び生体試料中の測定対象物質を定量する方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/007744 Continuation WO2017150516A1 (ja) | 2016-02-29 | 2017-02-28 | 生体試料中の測定対象物質を定量するためのキット及び生体試料中の測定対象物質を定量する方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
US20180372638A1 US20180372638A1 (en) | 2018-12-27 |
US10816469B2 true US10816469B2 (en) | 2020-10-27 |
Family
ID=59744146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/115,593 Active 2037-10-03 US10816469B2 (en) | 2016-02-29 | 2018-08-29 | Kit for quantitatively determining substance to be measured in biological sample and method for quantitatively determining substance to be measured in biological sample |
Country Status (5)
Country | Link |
---|---|
US (1) | US10816469B2 (zh) |
EP (1) | EP3425397B1 (zh) |
JP (1) | JP6532594B2 (zh) |
CN (1) | CN108700581A (zh) |
WO (1) | WO2017150516A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11486879B2 (en) * | 2017-03-30 | 2022-11-01 | Fujifilm Corporation | Kit and method for measuring measurement target substance in biological sample |
US11519860B2 (en) * | 2017-03-30 | 2022-12-06 | Fujifilm Corporation | Kit, method and reagent for measuring measurement target substance |
US11674966B2 (en) | 2017-03-30 | 2023-06-13 | Fujifilm Corporation | Kit and method for measuring measurement target substance in biological sample |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190120330A (ko) | 2017-03-30 | 2019-10-23 | 후지필름 가부시키가이샤 | 측정 대상 물질을 측정하기 위한 키트, 방법 및 시약 |
JP6857714B2 (ja) | 2017-03-30 | 2021-04-14 | 富士フイルム株式会社 | 生体試料中の測定対象物質を測定するためのキット及び方法 |
CN110506208A (zh) | 2017-03-30 | 2019-11-26 | 富士胶片株式会社 | 用于测定活体样品中的测定对象物质的试剂盒及方法 |
WO2022065052A1 (ja) * | 2020-09-24 | 2022-03-31 | 株式会社Jvcケンウッド | 捕捉用抗体、固相担体、検出用抗体、固相担体粒子、並びに検出対象物質の測定キット及び測定方法 |
JPWO2023136043A1 (zh) * | 2022-01-13 | 2023-07-20 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001021563A (ja) | 1999-07-06 | 2001-01-26 | Nitto Denko Corp | 特異的結合体 |
CN1462885A (zh) | 2002-05-29 | 2003-12-24 | 中国科学院力学研究所 | 共价固定生物分子的蛋白质芯片及其制备方法 |
US20060148097A1 (en) | 2005-01-06 | 2006-07-06 | Sysmex Corporation | Test strip for immunochromatography |
JP2009133740A (ja) | 2007-11-30 | 2009-06-18 | Tanaka Kikinzoku Kogyo Kk | イムノクロマトグラフィー用試験片 |
JP2010181155A (ja) | 2009-02-03 | 2010-08-19 | Fujifilm Corp | 物質固定基板の製造方法 |
US20110065213A1 (en) | 2009-09-11 | 2011-03-17 | Kasagi Noriyuki | Method for immunoassay using latex particles |
US20130078738A1 (en) | 2011-09-28 | 2013-03-28 | Fujifilm Corporation | Method for measuring substance to be measured using fluorescent particles, test subsance measurement chip, and test subsance measurement kit |
US20130078737A1 (en) | 2011-09-26 | 2013-03-28 | Fujifilm Corporation | Thyroxine immunoassay using fluorescent particles |
CN103792211A (zh) | 2014-01-27 | 2014-05-14 | 暨南大学 | 一种表面等离子体共振生物芯片及其制备方法与应用 |
JP2014235081A (ja) | 2013-06-03 | 2014-12-15 | コニカミノルタ株式会社 | 免疫染色方法、蛍光免疫染色用前処理液および免疫染色用キット |
WO2015017285A2 (en) | 2013-07-30 | 2015-02-05 | Bio-Rad Laboratories, Inc. | Multiplex blocker beads for immunoassays |
-
2017
- 2017-02-28 CN CN201780014062.XA patent/CN108700581A/zh active Pending
- 2017-02-28 WO PCT/JP2017/007744 patent/WO2017150516A1/ja active Application Filing
- 2017-02-28 EP EP17759982.6A patent/EP3425397B1/en active Active
- 2017-02-28 JP JP2018503322A patent/JP6532594B2/ja active Active
-
2018
- 2018-08-29 US US16/115,593 patent/US10816469B2/en active Active
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001021563A (ja) | 1999-07-06 | 2001-01-26 | Nitto Denko Corp | 特異的結合体 |
CN1462885A (zh) | 2002-05-29 | 2003-12-24 | 中国科学院力学研究所 | 共价固定生物分子的蛋白质芯片及其制备方法 |
US20060148097A1 (en) | 2005-01-06 | 2006-07-06 | Sysmex Corporation | Test strip for immunochromatography |
JP2006189317A (ja) | 2005-01-06 | 2006-07-20 | Sysmex Corp | イムノクロマトグラフ法用試験具 |
JP2009133740A (ja) | 2007-11-30 | 2009-06-18 | Tanaka Kikinzoku Kogyo Kk | イムノクロマトグラフィー用試験片 |
JP2010181155A (ja) | 2009-02-03 | 2010-08-19 | Fujifilm Corp | 物質固定基板の製造方法 |
US20110065213A1 (en) | 2009-09-11 | 2011-03-17 | Kasagi Noriyuki | Method for immunoassay using latex particles |
CN102023209A (zh) | 2009-09-11 | 2011-04-20 | 富士胶片株式会社 | 使用胶乳粒子的免疫测定方法 |
US20130078737A1 (en) | 2011-09-26 | 2013-03-28 | Fujifilm Corporation | Thyroxine immunoassay using fluorescent particles |
JP2013083633A (ja) | 2011-09-26 | 2013-05-09 | Fujifilm Corp | 蛍光粒子を用いたサイロキシン免疫アッセイ |
US20130078738A1 (en) | 2011-09-28 | 2013-03-28 | Fujifilm Corporation | Method for measuring substance to be measured using fluorescent particles, test subsance measurement chip, and test subsance measurement kit |
CN103033492A (zh) | 2011-09-28 | 2013-04-10 | 富士胶片株式会社 | 使用了荧光粒子的检测对象物质的检测方法 |
JP2014235081A (ja) | 2013-06-03 | 2014-12-15 | コニカミノルタ株式会社 | 免疫染色方法、蛍光免疫染色用前処理液および免疫染色用キット |
WO2015017285A2 (en) | 2013-07-30 | 2015-02-05 | Bio-Rad Laboratories, Inc. | Multiplex blocker beads for immunoassays |
CN103792211A (zh) | 2014-01-27 | 2014-05-14 | 暨南大学 | 一种表面等离子体共振生物芯片及其制备方法与应用 |
Non-Patent Citations (7)
Title |
---|
"International Preliminary Report on Patentability (Form PCT/IPEA/409) of PCT/JP2017/007744", dated Apr. 17, 2018, with English translation thereof, pp. 1-13. |
"International Search Report (Form PCT/ISA/210) of PCT/JP2017/007744", dated May 30, 2017, with English translation thereof, pp. 1-5. |
"Office Action of China Counterpart Application", dated Jun. 28, 2020, with English translation thereof, pp. 1-16. |
"Search Report of Europe Counterpart Application", dated Dec. 7, 2018, p. 1-p. 8. |
Adriano Ambrosi et al., "Enhanced Gold Nanoparticle Based ELISA for a Breast Cancer Biomarker," Anal. Chem., vol. 82, Issue 3, Feb. 1, 2010, pp. 1151-1156. |
Sandeep Kumar Vashist et al., "One-step antibody immobilization-based rapid and highly-sensitive sandwich ELISA procedure for potential in vitro diagnostics," scientific reports, vol. 4, Issue 1, Mar. 18, 2014 , pp. 1-7. |
Zhou Yu et al., "An enhanced ELISA based on modified colloidal gold nanoparticles for the detection of Pb(II).," Biosensors & Bioelectronics, vol. 26, Issue 8, Feb. 9, 2011, pp. 3700-3704. |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11486879B2 (en) * | 2017-03-30 | 2022-11-01 | Fujifilm Corporation | Kit and method for measuring measurement target substance in biological sample |
US11519860B2 (en) * | 2017-03-30 | 2022-12-06 | Fujifilm Corporation | Kit, method and reagent for measuring measurement target substance |
US11674966B2 (en) | 2017-03-30 | 2023-06-13 | Fujifilm Corporation | Kit and method for measuring measurement target substance in biological sample |
Also Published As
Publication number | Publication date |
---|---|
JPWO2017150516A1 (ja) | 2018-12-27 |
CN108700581A (zh) | 2018-10-23 |
US20180372638A1 (en) | 2018-12-27 |
JP6532594B2 (ja) | 2019-06-19 |
EP3425397B1 (en) | 2020-05-27 |
WO2017150516A1 (ja) | 2017-09-08 |
EP3425397A1 (en) | 2019-01-09 |
EP3425397A4 (en) | 2019-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10816469B2 (en) | Kit for quantitatively determining substance to be measured in biological sample and method for quantitatively determining substance to be measured in biological sample | |
US10883986B2 (en) | Kit for quantitatively determining bile acid in biological sample, and method for quantitatively determining bile acid in biological sample | |
EP2995952B1 (en) | Reagent kit, measurement kit, and method of measuring test substance | |
JP5363631B2 (ja) | 蛍光粒子を用いた検出対象物質の検出方法 | |
EP2573570B1 (en) | Cortisol immunoassay using fluorescent particles | |
EP3767294A1 (en) | Reagent kit, measurement kit, and measurement method | |
US20200408773A1 (en) | Reagent kit, measurement kit, and measurement method | |
US11255849B2 (en) | Kit for quantitatively determining substance to be measured in biological sample | |
EP2573561B1 (en) | Thyroxine immunoassay using fluorescent particles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
AS | Assignment |
Owner name: FUJIFILM CORPORATION, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KASAGI, NORIYUKI;CHIKU, HIROYUKI;SIGNING DATES FROM 20180531 TO 20180606;REEL/FRAME:046774/0570 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |